SciClone Pharmaceuticals (Holdings) Limited

SEHK:6600 Stock Report

Market Cap: HK$11.3b

SciClone Pharmaceuticals (Holdings) Future Growth

Future criteria checks 3/6

SciClone Pharmaceuticals (Holdings) is forecast to grow earnings and revenue by 4.7% and 12.9% per annum respectively. EPS is expected to grow by 1.3% per annum. Return on equity is forecast to be 24.1% in 3 years.

Key information

4.7%

Earnings growth rate

1.3%

EPS growth rate

Pharmaceuticals earnings growth10.7%
Revenue growth rate12.9%
Future return on equity24.1%
Analyst coverage

Low

Last updated03 Apr 2024

Recent future growth updates

No updates

Recent updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31
SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02
Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04
We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02
An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Earnings and Revenue Growth Forecasts

SEHK:6600 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20254,0861,233N/AN/A1
12/31/20243,6101,150N/A1,0571
12/31/20233,1561,1221,3271,404N/A
9/30/20233,0171,0381,1851,322N/A
6/30/20232,8789531,0431,239N/A
3/31/20232,8149041,0151,211N/A
12/31/20222,7508559871,184N/A
9/30/20222,7068441,1071,214N/A
6/30/20222,6628331,2261,245N/A
3/31/20222,5908781,0321,137N/A
12/31/20212,5189238391,029N/A
9/30/20212,259837506840N/A
6/30/20212,089779358724N/A
3/31/20212,004766435853N/A
12/31/20201,919754512981N/A
9/30/20202,001817657974N/A
12/31/20191,7086159991,032N/A
12/31/20181,409535143167N/A
12/31/20171,21320143154N/A
6/30/20171,166294N/A242N/A
3/31/20171,146258N/A187N/A
12/31/20161,112213N/A240N/A
9/30/20161,060246N/A221N/A
6/30/20161,072257N/A231N/A
3/31/20161,034183N/A214N/A
12/31/20151,021191N/A211N/A
9/30/2015991130N/A200N/A
6/30/2015913102N/A210N/A
3/31/2015879186N/A222N/A
12/31/2014836156N/A171N/A
9/30/2014774133N/A148N/A
6/30/2014790140N/A173N/A
3/31/201477068N/A17N/A
12/31/201376966N/A58N/A
9/30/201378078N/A88N/A
6/30/2013816-56N/A87N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6600's forecast earnings growth (4.7% per year) is above the savings rate (2.2%).

Earnings vs Market: 6600's earnings (4.7% per year) are forecast to grow slower than the Hong Kong market (11.8% per year).

High Growth Earnings: 6600's earnings are forecast to grow, but not significantly.

Revenue vs Market: 6600's revenue (12.9% per year) is forecast to grow faster than the Hong Kong market (7.9% per year).

High Growth Revenue: 6600's revenue (12.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6600's Return on Equity is forecast to be high in 3 years time (24.1%)


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.